Mohamed Elkasaby, MD
-
Specialty: Neurology, Neurology-Behavioral Neurology and Neuropsychiatry, Neurology-Movement Disorders
View Expertise -
Primary Location: 11100 Euclid Ave (0 mi.)
Other Locations - Languages Spoken: English, German, Arabic
Office Locations
UH Cleveland Medical Center Bolwell (0 mi.)
11100 Euclid Ave
Bolwell 5th Floor
Cleveland, OH 44106
216-844-3192
Biography: Mohamed Elkasaby, MD
Expertise
Titles
- Assistant Professor, CWRU School of Medicine
Education
Fellowship | Behavioral Neurology and Neuropsychiatry
Behavioral Neurology and Neuropsychiatry - UH Cleveland Medical Center (2021 - 2022)
Fellowship | Movement Disorders
Movement Disorders - UH Cleveland Medical Center (2019 - 2021)
Residency | Neurology
Neurology - Helios Clinic Bonn – Rhein-Sieg Hospital (2012 - 2018)
Medical Education
Ain Shams University Faculty Of Medicine (2009)
About
Mohamed Elkasaby, MD, is a neurologist at University Hospitals Cleveland Medical Center. He is trained in movement disorders and cognitive neurology. His special interests include Parkinson’s disease, dementia, tremor, dystonia, botulinum toxin injections and deep brain stimulation.
Dr. Elkasaby earned his medical degree from Ain Shams University in Egypt, where he completed his internship. He completed his neurology residency in Germany and worked as a neurology specialist there. He is board certified in neurology in Germany. He is a fellow of the European Board of Neurology.
He completed two years of clinical fellowship in movement disorders and neuromodulation at University Hospitals, and a clinical fellowship in behavioral neurology and neuropsychiatry at University Hospitals.
Dr. Elkasaby has written several peer-reviewed articles, abstracts and book chapters focusing on movement disorders and dementia. Dr. Elkasaby has also served as a reviewer for prominent medical journals focusing on movement disorders and dementia. He is a Steering Committee Member at the Alzheimer’s Disease Cooperative Study (ADCS), which is a part of the National Institute on Aging (NIA) Division of Neuroscience’s effort to facilitate the discovery, development and testing of new drugs for the treatment of Alzheimer’s Disease, and is a part of Alzheimer’s Disease Prevention Initiative as well. Dr. Elkasaby is a member of the American Academy of Neurology, the European Academy of Neurology, the Movement Disorder Society and the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment.
Research & Publications
Research Interests
Cognitive aspects of movement disorders, Parkinson's disease, Dementia with Lewy bodies, Clinical Trials for Alzheimer's Disease and Parkinson's disease
Patient Experience Reviews
Dr. Elkasaby was very thorough. While he was a few minutes late in seen Judy, he apologized for that and more than made up for that problem. He is very good at what he does.
Great experience. Very understanding and helpful.
Very pleased with Dr. Elkasabyhe is kind, understanding and a perfect fit for our family!!!He's very busy!
Very good experience with the doctor.
Very good doctor and staff would highly recommend
Care provider was thoughtful and caring.
I felt very comfortable with my Dr. & had a very favorable first visit
All details were explained and not question nor concern was left without answer
Excellent care and experience.
Dr. Elkasaby listens to my concerns. He is very kind and easy to understand when he explains things to me. My daughter brings me to my appointments and he includes her in the conversations and answers her questions and concerns.
The care provider was attentive and authentic and gave me a positive feeling of taking care of my requests.
The physician was great. He explained everything to me and was thorough and felt he answered all of my questions. ***
Was very pleased and impressed with everyone who helped me during the visit
Good experience
Very caring and understanding. Great explaining details.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Mohamed Elkasaby did not disclose any Outside Relationships with Industry.